Illumina Inc
ILU
Company Profile
Business description
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Contact
5200 Illumina Way
San DiegoCA92122
USAT: +1 858 202-4500
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
8,970
Stocks News & Analysis
stocks
Our top ASX picks in every sector
These companies are our top choices for investors wanting to boost Aussie exposure.
stocks
Potentially catastrophic ruling for ASX company
We raise our risk and uncertainty rating to reflect the impact of the ruling.
stocks
4 charts on Nvidia’s record $4 trillion market cap
Shares of the semiconductor giant have rocketed 280% over the past two years amid the AI boom.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,875.30 | 60.00 | 0.68% |
| CAC 40 | 7,807.86 | 0.31 | -0.00% |
| DAX 40 | 24,200.92 | 40.28 | 0.17% |
| Dow JONES (US) | 44,459.65 | 88.14 | 0.20% |
| FTSE 100 | 8,998.80 | 0.74 | 0.01% |
| HKSE | 24,590.12 | 386.80 | 1.60% |
| NASDAQ | 20,640.33 | 54.80 | 0.27% |
| Nikkei 225 | 39,678.02 | 218.40 | 0.55% |
| NZX 50 Index | 12,689.63 | 10.94 | 0.09% |
| S&P 500 | 6,268.56 | 8.81 | 0.14% |
| S&P/ASX 200 | 8,630.30 | 59.90 | 0.70% |
| SSE Composite Index | 3,505.00 | 14.65 | -0.42% |